Search

Your search keyword '"G. Materazzi"' showing total 392 results

Search Constraints

Start Over You searched for: Author "G. Materazzi" Remove constraint Author: "G. Materazzi"
392 results on '"G. Materazzi"'

Search Results

201. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.

202. Minimally invasive video-assisted thyroidectomy: reflections after more than 2400 cases performed.

203. Track Recurrence After Robotic Transaxillary Thyroidectomy: A Case Report Highlighting the Importance of Controlled Surgical Indications and Addressing Unprecedented Complications.

204. Can Total Thyroidectomy Be Safely Performed by Residents?: A Comparative Retrospective Multicenter Study.

205. Indeterminate Single Thyroid Nodule: Synergistic Impact of Mutational Markers and Sonographic Features in Triaging Patients to Appropriate Surgery.

206. Minimally invasive video-assisted thyroidectomy (MIVAT) from A to Z.

207. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.

208. Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.

209. Molecular Targeted Therapies of Aggressive Thyroid Cancer.

210. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.

211. Selective use of vandetanib in the treatment of thyroid cancer.

212. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?

213. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study.

214. New therapies for dedifferentiated papillary thyroid cancer.

215. Surgery for recurrent goiter: complication rate and role of the thyroid-stimulating hormone-suppressive therapy after the first operation.

216. Cabozantinib in Thyroid Cancer.

217. Sorafenib in the treatment of thyroid cancer.

218. E-selectin expression and BRAF status in papillary thyroid carcinomas: Correlation with clinicopathologic features.

219. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro.

220. CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo.

221. Cosmetic result and overall satisfaction after minimally invasive video-assisted thyroidectomy (MIVAT) versus robot-assisted transaxillary thyroidectomy (RATT): a prospective randomized study.

222. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.

223. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.

224. Role of 18F-DOPA PET/CT in diagnosis and follow-up of adrenal and extra-adrenal paragangliomas.

225. The impact of the Harmonic FOCUS™ on complications in thyroid surgery: a prospective multicenter study.

226. Sorafenib and thyroid cancer.

227. Follicular-derived neoplasms: morphometric and genetic differences.

228. Conservative management of a tracheal leakage occurring 40 days after robotic thyroidectomy.

230. Performance of chloride/phosphate test in patients with primary hyperparathyroidism. Is it related to calcium level?

231. Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation.

232. Increased costs of perioperative risk assessment for thyroid surgery in elderly people (over 80 years) presenting with benign disease.

233. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.

234. Bupivacaine 0.5% versus ropivacaine 0.75% wound infiltration to decrease postoperative pain in total thyroidectomy, a prospective controlled study.

235. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.

236. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction.

237. Recurrent laryngeal nerve injury in video-assisted thyroidectomy: lessons learned from neuromonitoring.

238. Evaluation of a preoperative pain score in response to pressure as a marker of postoperative pain and drugs consumption in surgical thyroidectomy.

239. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer.

240. Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment.

241. Minimally invasive video assisted thyroidectomy versus endoscopic thyroidectomy via the areola approach: a retrospective analysis of safety, postoperative recovery, and patient satisfaction.

242. CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas.

244. No outcome differences between a laparoscopic and retroperitoneoscopic approach in synchronous bilateral adrenal surgery.

245. Is elastography actually useful in the presurgical selection of thyroid nodules with indeterminate cytology?

247. Mini-invasive video-assisted surgery of the thyroid and parathyroid glands: a 2011 update.

248. RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).

249. Why monitor the recurrent laryngeal nerve in thyroid surgery?

250. Evaluation of a new ultrasonic device in thyroid surgery: comparative randomized study.

Catalog

Books, media, physical & digital resources